WHO, Essential medicines and health products, Alerts [edited]<http://www.who.int/medicines/publications/drugalerts/drug_alert1-2017/en/#.WTa6lsW-1Bk.email>Medical product alert no. 1/2017--------------------------------Falsified meningococcal ACWY vaccine circulating in West AfricaThis Medical Product Alert relates to the circulation of a confirmed falsified meningococcal ACWY vaccine discovered in Niger.This product is used to immunise against meningococcal disease serogroups A, C, W, and Y. Meningococcal meningitis vaccine is listed as a WHO Essential Medicine.On 31 May 2017, the manufacturer ""Bio-Manguinhos/Fiocruz"" informed WHO that a falsified version of the following product was available in Niger:Product name: Polysaccharide Meningococcal ACYW VaccineProduct batch number: 089UMH002 ZExpiry date: 092017Date of manufacture: 092014The label on the product claims that it is manufactured by Bio-Manguinhos/Fiocruz and is presented in vials of 10 doses each.Photographs of the falsified vaccine are available in annex [available at the source URL above]. This falsified product has not yet been subject to laboratory analysis.The manufacturer Bio-Manguinhos/Fiocruz has stated that:- they do not manufacture Polysaccharide Meningococcal ACWY Vaccine;- based on examination of the photographs they can confirm that this packaging is falsified.No adverse events following immunisation attributed to this falsified vaccine are known to have been reported at this stage.On the basis of the above information, any Meningococcal ACWY Vaccine claiming to be manufactured by ""Bio-Manguinhos/Fiocruz"", should be considered falsified and reported.Advice to health care professionals, patients, and national authorities----------------------------------------------------------------------If you are in possession of this vaccine, please do not use, contact a healthcare professional as soon as possible for advice, and report the incident to your local Ministry of Public Health/National Medicines Regulatory Authorities/National Pharmacovigilance Centre.Please seek immediate advice from a qualified healthcare professional if you have been immunised with this falsified vaccine, or if you suffer an adverse event following immunisation with this vaccine, and report the incident as indicated above.Members of the public who are aware of falsified medical products sold by various retailers should report to their national health authorities.It is necessary to ensure that all medical products are obtained from authentic and reliable sources. Their authenticity and origin should be carefully checked and verified with manufacturers before use. WHO requests increased vigilance for the supply chains of countries likely to be affected by these falsified products. Vigilance should include hospitals, clinics, pharmacies and any other suppliers of medical products.Authorities are asked to immediately notify WHO if these falsified products are discovered in their country. If you have any information on their supply and/or distribution please contact <rapidalert@who.int>.WHO will issue Medical Product Alerts to ensure a timely, proportionate, accurate, and consistent response to health events arising from substandard and falsified medical products, which represent a significant threat to international public health. Alerts will be published on the WHO website, and will remain on the website for a period of 5 years before archiving. Alerts may also be disseminated to the current known networks of National Medicines Regulatory Authorities dealing with defective medicines, International Health Regulation Focal Points, substandard and falsified surveillance and monitoring focal points, and National pharmacovigilance and vaccine networks.WHO Surveillance and Monitoring - Rapid Alert---------------------------------------------Substandard, spurious, falsely labelled, falsified, and counterfeit (SSFFC) medical products. All WHO Drug Alerts are available at <http://www.who.int/medicines/publications/drugalerts/en/>--Communicated by:ProMED-mail<promed@promedmail.org>[The distribution of substandard/counterfeit drugs, especially antibiotics and antimalarial agents is a growing problem worldwide, but is most often reported in less-developed countries (<http://cmr.asm.org/content/28/2/443.full>, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137817/>, and <http://www.ncbi.nlm.nih.gov/books/NBK202527/>). Also see <http://www.epnetwork.org/en/centre-of-excellence/toolkit-quality-of-medicines>.Use of a polysaccharide meningococcal ACWY vaccine that may contain no or substandard product in West Africa in the face of the current ongoing meningococcal meningitis outbreak is obviously a major problem. - Mod.MLA HealthMap/ProMED-mail map can be accessed at: <http://healthmap.org/promed/p/40192>.]
